Journal
CLINICAL INFECTIOUS DISEASES
Volume 71, Issue 6, Pages 1502-1510Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciz985
Keywords
hepatitis C; HIV; men-who-have-sex-with-men; elimination; treatment-as-prevention
Categories
Funding
- Gilead Sciences, Inc
- Australian Government Department of Health and Ageing
- National Health and Medical Research Council
- Gilead Sciences, Inc.
Ask authors/readers for more resources
Background Microelimination of hepatitis C virus (HCV) among people living with human immunodeficiency virus (HIV) may be feasible in Australia, given unrestricted access to direct-acting antiviral (DAA) therapy from 2016. Our aim was to evaluate progress towards elimination goals within HIV/HCV-coinfected adults in Australia following universal DAA access. Methods The CEASE prospective cohort study enrolled adults with HIV/HCV, irrespective of viremic status, from 14 primary and tertiary clinics in Australia. Annual and cumulative HCV treatment uptake, outcome, and HCV RNA prevalence were evaluated, with follow-up through May 2018 (median follow-up, 2.63 years). Factors associated with DAA uptake were analyzed. Results Between July 2014 and March 2017, 402 participants who were HIV/HCV antibody positive were enrolled (95% male [80% gay and bisexual men,], 13% cirrhosis, 80% history of injecting drug use [39% currently injecting]). Following universal DAA access, annual HCV treatment uptake in those eligible increased from 7% and 11% per year in 2014 and 2015, respectively, to 80% in 2016. By 2018, cumulative HCV treatment uptake in those ever eligible for treatment was 91% (336/371). HCV viremic prevalence declined from 82% (95% CI, 78-86%) in 2014 to 8% (95% CI, 6-12%) in 2018. Reinfection was reported in only 5 participants for a reinfection incidence of 0.81 per 100 person-years (95% CI, 0.34-1.94). Conclusions High uptake and effectiveness of unrestricted DAA therapy in Australia have permitted rapid treatment scale-up, with a dramatic reduction in HCV infection burden and low reinfection rate among people living with HIV, suggesting that microelimination is feasible. Clinical Trials Registration NCT02102451. Linkage to care and unrestricted access to direct-acting antiviral therapy have facilitated rapid hepatitis C virus (HCV) treatment scale-up among people living with human immunodeficiency virus in Australia, reducing HCV viremic prevalence, and highlighting the potential population-level impact of HCV treatment-as-prevention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available